Novo Nordisk A/S said a long-term study showed that its hemophilia A treatment, called NovoEight, maintained its potency even after being stored at temperatures of 40 degrees C.
Hemophilia A patients often struggle with treatment storage issues, the Danish drugmaker said in a news release.

The storage conditions for NovoEight allow the therapy to be stored at temperatures of up to 40 degrees for three months.
